Compare GEVO & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEVO | PRQR |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.1M | 250.7M |
| IPO Year | 2011 | 2014 |
| Metric | GEVO | PRQR |
|---|---|---|
| Price | $2.19 | $2.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $8.13 | ★ $8.14 |
| AVG Volume (30 Days) | ★ 2.8M | 642.3K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,932,000.00 | $18,859,556.00 |
| Revenue This Year | $927.85 | N/A |
| Revenue Next Year | $12.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 675.75 | N/A |
| 52 Week Low | $0.92 | $1.07 |
| 52 Week High | $2.98 | $3.10 |
| Indicator | GEVO | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 49.30 |
| Support Level | $2.16 | $2.03 |
| Resistance Level | $2.24 | $2.25 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 27.54 | 47.62 |
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.